Next Generation Immunotherapies

Peter Keller, Vice President Business Development, Selecta Biosciences joined us at the World Vaccine Congress Lyon 2012 to present on Synthetic Vaccine Particle technology. This technology has been created to help maximise the potential for the use of nanoparticles in vaccines. Nanoparticles have the optimal size for recognition by the immune system: The human immune system has evolved to recognize …